Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | FPR2 | P25090 | 4/20 | 0.54 |
| ▸ | PROKR1 | Q8TCW9 | 4/20 | 0.54 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.50 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.50 |
| ▸ | HTR2C | P28335 | 2/20 | 0.49 |
| ▸ | HTR2B | P41595 | 2/20 | 0.49 |
| ▸ | HTR2A | P28223 | 1/20 | 0.47 |
| ▸ | HTR7 | P34969 | 1/20 | 0.47 |
| ▸ | MAOA | P21397 | 1/20 | 0.47 |
| ▸ | MAOB | P27338 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17848470 | 0.91 | HTR2C (0.58) | HRH3SMN1; SMN2SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL20788247 | 0.91 | HTR2C (0.58) | HRH3SMN1; SMN2SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL10261843 | 0.91 | HTR2C (0.58) | HRH3SMN1; SMN2SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL11068906 | 0.85 | HRH3 (0.51) | HRH3SMN1; SMN2FPR2PROKR1SLC6A4 | |
| SCHEMBL14577976 | 0.85 | HRH3 (0.67) | HRH3SMN1; SMN2HTR2CHTR2BMAOA | |
| SCHEMBL188685 | 0.83 | HRH3 (0.65) | HRH3SMN1; SMN2MAOAMAOB | |
| SCHEMBL5543389 | 0.83 | HRH3 (0.65) | HRH3SMN1; SMN2FPR2PROKR1HTR2C | |
| SCHEMBL13946926 | 0.82 | HRH3 (0.59) | HRH3SMN1; SMN2SLC6A2SLC6A3HTR2C | |
| SCHEMBL27028609 | 0.82 | SLC6A4 (0.62) | FPR2PROKR1SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL17433283 | 0.81 | HRH3 (0.50) | HRH3SMN1; SMN2HTR2CHTR2BMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3681883-B1 | DIPHENYL DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2024-02-21 | — | — | EP | disclosed |
| CN-111094278-B | Diphenyl derivative and use thereof | 诺华股份有限公司 | 2023-07-14 | — | — | CN | disclosed |
| EP-3681883-A1 | DIPHENYL DERIVATIVES AND USES THEREOF | Novartis AG (CH) | 2020-07-22 | — | — | EP | disclosed |
| CN-111094278-A | Diphenyl derivatives and their use | 诺华股份有限公司 | 2020-05-01 | — | — | CN | disclosed |
| US-10633350-B2 | Diphenyl derivatives and uses thereof | NOVARTIS AG (CH) | 2020-04-28 | — | — | US | disclosed |
| US-20190127374-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2019-05-02 | — | — | US | disclosed |
| US-20190127373-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2019-05-02 | — | — | US | disclosed |
| US-20190127375-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2019-05-02 | — | — | US | disclosed |
| WO-2019053090-A1 | DIPHENYL DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2019-03-21 | — | — | WO | disclosed |
| US-20190077773-A1 | DIPHENYL DERIVATIVES AND USES THEREOF | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2019-03-14 | — | — | US | disclosed |
| US-7521445-B2 | Heterocyclic substituted carbonyl derivatives and their use as dopamine D3 receptor ligands | AVENTIS PHARMACEUTICALS INC. (US) | 2009-04-21 | — | — | US | disclosed |
| EP-1632483-B1 | HETEROCYCLIC SUBSTITUTED CARBONYL DERIVATIVES AND THEIR USE AS DOPAMINE D3 RECEPTOR LIGANDS | AVENTIS PHARMA INC (US) | 2008-10-29 | — | — | EP | disclosed |
| EP-1935887-A1 | Heterocyclic substituted carbonyl derivatives and their use as dopamine D3 receptor ligands | Aventis Pharmaceuticals, Inc. (US) | 2008-06-25 | — | — | EP | disclosed |
| US-20070161641-A1 | Novel heterocyclic substituted carbonyl derivatives and their use as dopamine D3 receptor ligands | AVENTIS PHARMACEUTICALS INC. (US) | 2007-07-12 | — | — | US | disclosed |
| US-20070161641-A1 | Novel heterocyclic substituted carbonyl derivatives and their use as dopamine D3 receptor ligands | AVENTIS PHARMACEUTICALS INC. (US) | 2007-07-12 | — | — | US | disclosed |
| US-20070055065-A1 | N-sulphonylated amino acid derivatives, method for the production and use thereof | CURACYTE CHEMISTRY GMBH (DE) | 2007-03-08 | — | — | US | disclosed |
| US-20070055065-A1 | N-sulphonylated amino acid derivatives, method for the production and use thereof | CURACYTE CHEMISTRY GMBH (DE) | 2007-03-08 | — | — | US | disclosed |
| US-7186724-B2 | Heterocyclic substituted carbonyl derivatives and their use as dopamine D3 receptor ligands | AVENTIS PHARMACEUTICALS INC. (US) | 2007-03-06 | — | — | US | disclosed |
| US-7186724-B2 | Heterocyclic substituted carbonyl derivatives and their use as dopamine D3 receptor ligands | AVENTIS PHARMACEUTICALS INC. (US) | 2007-03-06 | — | — | US | disclosed |
| WO-2004101507-A2 | N-SULPHONYLATED AMINO ACID DERIVATIVES AND USE THEREOF AS MATRIPTASE INHIBITORS | CURACYTE CHEMISTRY GMBH (DE) | 2004-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190077773-A1 | DIPHENYL DERIVATIVES AND USES THEREOF | MYOF, NGF, MUSK | HRH3 4847/4885SMN1; SMN2 7/4885FPR2 3754/4885 |
| US-20190127373-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | RET, ROR1, BRAF | HRH3 1340/4885SMN1; SMN2 989/4885FPR2 2607/4885 |
| US-20190127375-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | RET, ROR1, BRAF | HRH3 1340/4885SMN1; SMN2 989/4885FPR2 2607/4885 |
| US-20070055065-A1 | N-sulphonylated amino acid derivatives, method for the production and use thereof | DNPEP, ANPEP, PEPD | HRH3 2066/4885SMN1; SMN2 1094/4885FPR2 722/4885 |
| US-20190127374-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | RET, ROR1, BRAF | HRH3 1340/4885SMN1; SMN2 989/4885FPR2 2607/4885 |
| US-10633350-B2 | Diphenyl derivatives and uses thereof | MYOF, NGF, MUSK | HRH3 4847/4885SMN1; SMN2 7/4885FPR2 3754/4885 |
| US-20070161641-A1 | Novel heterocyclic substituted carbonyl derivatives and their use as dopamine D3 receptor ligands | DRD3, DRD2, HTR3C | HRH3 59/4885SMN1; SMN2 2313/4885FPR2 1687/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.